For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

31st Aug 21

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

  • Topical treatment safe and well tolerated in study of healthy volunteers
  • Full inhibition of lysyl oxidase enzymes achieved in skin with minimal systemic exposure
  • Collaboration with research team led by Professor Fiona Wood AM planning for trial in patients with established scars to commence in Q4 2021
Read full media release - pdf
17th Aug 21

Pharmaxis Grants Aptar Pharma Exclusive Option to Develop and Promote High Payload Dry Powder Inhaler

  • Drug delivery solutions developer Aptar Pharma acquires an exclusive 12-month option for a worldwide license to the “Orbital” technology for $US2.5m plus sales royalties
  • Pharmaxis receives a US$250k upfront fee for the option grant
  • Orbital dry powder respiratory inhaler developed by Pharmaxis delivers large payloads of drug in a convenient easy-to-use format
  • Pharmaxis retains rights to inhaled mannitol products delivered via the Orbital inhaler
Read full media release - pdf
5th Aug 21

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

  • Data Presented from Collaboration of Pharmaxis and University of Rochester Medical Center at US Scientific Meeting
  • Combination of PXS-5505 and Standard of Care Demonstrates a Novel Therapeutic Strategy for Liver Cancer
Read full media release - pdf